Ascelia Pharma AB (publ)

Stockholm Stock Exchange ACE.ST

Ascelia Pharma AB (publ) Operating Income for the year ending December 31, 2023: USD -10.95 M

Ascelia Pharma AB (publ) Operating Income is USD -10.95 M for the year ending December 31, 2023, a 22.02% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Ascelia Pharma AB (publ) Operating Income for the year ending December 31, 2022 was USD -14.04 M, a 7.56% change year over year.
Ascelia Pharma AB (publ) Operating Income for the year ending December 31, 2021 was USD -15.19 M, a -34.13% change year over year.
Ascelia Pharma AB (publ) Operating Income for the year ending December 31, 2020 was USD -11.32 M, a -189.64% change year over year.
Ascelia Pharma AB (publ) Operating Income for the year ending December 31, 2019 was USD -3.91 M, a 2.56% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Stockholm Stock Exchange: ACE.ST

Ascelia Pharma AB (publ)

CEO	Mr. Magnus O. Corfitzen
IPO Date	March 13, 2019
Location	Sweden
Headquarters	Hyllie Boulevard 34
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.

Key trends

Past 5 years